Skip to main content

In March 2020, the World Health Organization declared a global COVID-19 pandemic and the UK announced a strict national lockdown. When Oxford University scientists were sent home, they rolled up their sleeves, switched on their computers and started to help develop new drugs to target SARS-CoV-2, the virus that causes COVID-19.

It began with a small group of scientists and their graduate students at the University of Oxford, who were joined by colleagues from Bristol University, Diamond Light Source and academics in France, Italy, and Spain – all working from home but coming together weekly on Zoom to tackle this terrifying disease.

Thus began an international collaboration involving 29 scientists around the world focused on understanding how SARS-COV-2 makes its worker proteins at the molecular level so we could develop novel antiviral drugs and block their production. Read the full story.

Related News

What does a statistician do for the England football team?

From squad selection to modelling how footballs behave at altitude, statistician Matt Penn explains how data is helping shape the modern game, and why coaches will always matter more than the numbers.

New evidence suggests vast hidden magma systems inside Mars

Researchers from the Departments of Earth Science and Statistics have found evidence that Mars once hosted enormous, Earth-like magmatic systems deep below its surface – even though the planet lacks the plate tectonics long considered essential for this kind of geological complexity. The findings open up new possibilities for how rocky planets become habitable.

Finding a needle in the genomic haystack: Targeting rare genes using statistical outliers

In statistical modelling, extreme outliers are often written off as 'noise'. But a new study by researchers from Oxford's Department of Statistics and Big Data Institute published this week in The American Journal of Human Genetics reverses that principle, using these outliers as the basis of a targeting system for locating rare, high-impact genetic mutations.